Syngeneic tumour models

Rapid advances of immuno-oncology have triggered a new need for tumour models growing in immunocompetent mice.

The syngeneic tumour models were mostly generated by inducing tumours in mice. Each model can develop subcutaneous or orthotopic tumours when implanted in the matching strain of immunocompetent mice.

Our approval for animal experimentation allows us to implant those models in C57BL/6, BALB/c, B6D2F1 and C3H. With a delay of a few weeks, we can obtain the agreement for other mouse strains.

In preclinical immuno-oncology, the syngeneic models are widely used to test combinations with approved Immune-Checkpoint Inhibitors like anti-PD1 or anti-PDL1. Amongst our syngeneic tumour models, we characterised several displaying primary resistances to anti-PD1 and/or anti-PDL1.

Why syngeneic models?

• A fully functional immune system

Unlike xenograft models, syngeneic models retain the complete host immune system which enables the study of tumour-immune interactions and the evaluation of immunomodulatory compounds under relevant physiological conditions.

• Immuno-oncology benchmarking

Our syngeneic models are widely used to test combinations with approved immune checkpoint inhibitors (anti-PD-1, anti-PD-L1). Several models have been characterised for their primary resistance to anti-PD-1 and/or anti-PD-L1, complementing our portfolio of secondary resistances.

• Well-characterised, data-backed models

Over 20 tumour cell lines have been examined for immune infiltration phenotype, TME composition, and responsiveness to SOC therapies. Models are described using historical in-house data, with molecular profiles available for key lines.